Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?

TheMotleyFool 
0 0 10.04.24
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg
 

Johnson Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of heart pump maker Abiomed for a whopping $16.6 billion. And recently, J announced yet another major deal: It is acquiring Shockwave Medical (NASDAQ: SWAV) for $13.1 billion.

What does this mean for the company, and does this move make Johnson Johnson an attractive option for growth investors?

Johnson Johnson's two key segments are medtech and innovative medicines. While the company invests in research and development to build out its pharma business, one way it has been bolstering its medtech division has been through acquisitions.

Continue reading


Source Fool.com

Abiomed Inc. Stock

€359.20
-


Show more
Like: 0
JNJ
Share

Comments

Not a member yet? Sign up for free!